gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · TVTXHealthcarePharmaceuticals

Travere Therapeutics, Inc. Common Stock (TVTX)

$52.42+6.09%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$52.42▲ 53.59% in range
Nov 4, 2025Low $26.79 · High $67.52Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Travere Therapeutics closed at $52.42 on Nov 4, up 6.09%, 22.4% below its 52-week closing high. Volume of 3.7M shares was 1.53× its 20-day average (above normal).

Split-adjusted performance: -6.4% over one month, +17.1% over six months, +51.8% over one year.

In the quarter ended Sep 30, 2026, revenue was $224.56M, up 36.2% from a year earlier, with a net margin of -23.3%.

Short interest was 10.9M shares at the Oct 15 settlement, down 13.8% from the prior report (12.1% of float, 5.2 days to cover).

Market cap$4.94B94.3M shares
Revenue · quarter$224.6M+36.2% YoY
Diluted EPS$-0.55−296.4% YoY
P/E · TTM—P/S 7.6×
Net margin-23.3%Gross 98.7%
Dividend yieldNone
52-week range26.79 – 67.52−22.4% from high
Volume3.7M1.53× 20-day avg
Volatility · 60d37.8%Annualised
Short % of float12.1%5.2 days to cover
Net cash-$131.7MCash $471.8M
Next earnings—Not scheduled
Split-adjusted performance
1W +3.1%1M −6.4%3M −16.1%6M +17.1%YTD +37.2%1Y +51.8%3Y +675.4%5Y +100.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum81
Revenue growth73
Net margin54
Value (low P/E)—
Size90

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short10.9M−13.8% vs prior
Days to cover5.2Settled Oct 15
% of float12.1%
Short vol. 10d51.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
TVTXTravere Therapeutics$52.42+6.09%+17.1%+36.2%−23.3%—$4.94B
DNTHDianthus Therapeutics$85.81+3.76%−5.1%+294.3%−6598.6%—$4.80BCompare
ERASErasca$14.91+1.84%+36.8%———$5.21BCompare
COGTCogent Biosciences$31.49+1.38%−12.2%———$5.46BCompare
DFTXDefinium Therapeutics$32.70−2.13%+39.6%———$4.39BCompare
MANEVeradermics, Incorporated$136.51+2.17%+24.4%———$5.70BCompare
ARQTArcutis Biotherapeutics$34.05+6.41%+40.9%+59.3%11.6%150.1$4.28BCompare
LQDALiquidia$47.38+12.27%+12.4%+1842.7%43.5%30.6$4.24BCompare
PTCTPTC Therapeutics$68.97+1.25%+3.6%+69.6%−14.4%—$5.76BCompare

News about Travere Therapeutics

All news →
Here's What Key Metrics Tell Us About Travere (TVTX) Q3 EarningsZacks Investment Research · 2d ago▼ NegativeTravere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research · 2d ago▼ NegativeKuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law FirmGlobeNewswire Inc. · Jul 17, 2026▼ NegativeValidating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains MattersThe Motley Fool · May 10, 2026Neutral

Quick answers

What does Travere Therapeutics do?
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases.
What is TVTX's market cap?
$4.94B, based on the Nov 4 close of $52.42.
Does Travere Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of TVTX is sold short?
10.9M shares, 12.1% of float, as of Oct 15, 2026.
What sector is TVTX in?
Healthcare, in the Pharmaceuticals industry.

About Travere Therapeutics

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

HQ: San Diego, CA497 employeesListed Jul 23, 2003travere.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology